Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma

Haematologica

Volumn 97, Issue 7, 2012, Pages 1080-1084

  Sánchez Espiridión, Beatriz ^a,c   Martin Moreno, Ana M ^a   Montalbán, Carlos ^b   Jeffrey Medeiros, L ^a   Vega, Francisco ^a   Younes, Anas ^a   Piris, Miguel A ^c   Garcia, Juan F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Hodgkin's lymphoma; Outcome; Tumor associated macrophages

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; LYSOZYME; STAT1 PROTEIN;

ADULT; ARTICLE; CLASSICAL HODGKIN LYMPHOMA; DISEASE SPECIFIC SURVIVAL; FAILURE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; GENE EXPRESSION; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; MURAMIDASE; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; STAT1 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863961531     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.055459     Document Type: Article

References (24)

1. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer. 2008;122(4):769-76.
2. Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11(4):1467-73.
3. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25 (3):315-22.
4. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21): 2159-69.
5. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169-74.
6. Ree HJ, Kadin ME. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer. 1985;56(2): 333-8.
7. Coppleson LW, Rappaport H, Strum SB, Rose J. Analysis of the Rye classification of Hodgkin's disease. The prognostic significance of cellular composition. J Natl Cancer Inst. 1973;51(2):379-90.
8. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez-Verde L, Morente MM, Garcia-Cosio M, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662-8.
9. Devilard E, Bertucci F, Trempat P, Bouabdallah R, Loriod B, Giaconia A, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene.2002;21(19):3095-102.
10. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010; 362(10):875-85.
11. Carde P, Koscielny S, Franklin J, Axdorph U, Raemaekers J, Diehl V, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol. 2002;13 (Suppl 1):86-91.
12. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, D'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011;96(2):269-76.
13. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma. 2011;52(10): 1913-9
14. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2011; doi: 10.1093/annonc/mdr157.
15. Agostinelli C, Gallamini A, Rigacci L, Vitolo U, Stracqualursi L, Piccaluga P, et al. The prognostic value of biologic markers in classical Hodgkin lymphoma (cHL) patients. Ann Oncol. 2011;22:153-4.
16. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood.2009;113(12):2765-3775.
17. Sanchez-Espiridion B, Sanchez-Aguilera A, Montalban C, Martin C, Martinez R, Gonzalez-Carrero J, et al. A TaqMan lowdensity array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clin Cancer Res. 2009;15(4):1367-75.
18. Sanchez-Espiridion B, Montalban C, Lopez A, Menarguez J, Sabin P, Ruiz-Marcellan C, et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116(8): e12-7.
19. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60(4):278-83.
20. Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne RW. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis. 2004;63(7):774-84.
21. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605-12.
22. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology. 2010;77(6):301-8.
23. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26(3):440-6.
24. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristineprednisone. Clin Cancer Res. 2007;13(19): 5784-9.